Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Mutations in the E2-PePHD region of hepatitis C virus genotype-3a and correlation with response to interferon and ribavirin combination therapy in Pakistani patients.

Afzal S, Idrees M, Akram M, Awan Z, Khubaib B, Aftab M, Fatima Z, Badar S, Hussain A.

Virol J. 2010 Dec 31;7:377. doi: 10.1186/1743-422X-7-377.

2.

Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.

Bolcic F, Sede M, Moretti F, Westergaard G, Vazquez M, Laufer N, Quarleri J.

Arch Virol. 2012 Apr;157(4):703-11. doi: 10.1007/s00705-012-1230-1. Epub 2012 Jan 22.

PMID:
22270759
3.

Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome.

Gaudy C, Lambelé M, Moreau A, Veillon P, Lunel F, Goudeau A.

J Clin Microbiol. 2005 Feb;43(2):750-4.

4.

Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.

Hung CH, Lee CM, Lu SN, Lee JF, Wang JH, Tung HD, Chen TM, Hu TH, Chen WJ, Changchien CS.

J Viral Hepat. 2003 Mar;10(2):87-94.

PMID:
12614464
6.

Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.

Saito T, Ito T, Ishiko H, Yonaha M, Morikawa K, Miyokawa A, Mitamura K.

Am J Gastroenterol. 2003 Jun;98(6):1377-83.

PMID:
12818284
7.

Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response.

Sarrazin C, Kornetzky I, Rüster B, Lee JH, Kronenberger B, Bruch K, Roth WK, Zeuzem S.

Hepatology. 2000 Jun;31(6):1360-70.

PMID:
10827164
8.
9.

The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon.

Polyak SJ, Nousbaum JB, Larson AM, Cotler S, Carithers RL Jr, Gretch DR.

J Infect Dis. 2000 Aug;182(2):397-404. Epub 2000 Jul 14.

PMID:
10915068
10.

Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.

Vuillermoz I, Khattab E, Sablon E, Ottevaere I, Durantel D, Vieux C, Trepo C, Zoulim F.

J Med Virol. 2004 Sep;74(1):41-53.

PMID:
15258967
11.

Mutations in two PKR-binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsiveness.

Yokozaki S, Katano Y, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, Goto H.

J Med Virol. 2011 Oct;83(10):1727-32. doi: 10.1002/jmv.21959.

PMID:
21837788
12.

Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment.

Berg T, Mas Marques A, Höhne M, Wiedenmann B, Hopf U, Schreier E.

Hepatology. 2000 Dec;32(6):1386-95.

PMID:
11093746
14.

Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.

Muñoz de Rueda P, Casado J, Patón R, Quintero D, Palacios A, Gila A, Quiles R, León J, Ruiz-Extremera A, Salmerón J.

J Virol. 2008 Jul;82(13):6644-53. doi: 10.1128/JVI.02231-07. Epub 2008 Apr 30.

15.

Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy.

Sarrazin C, Bruckner M, Herrmann E, Rüster B, Bruch K, Roth WK, Zeuzem S.

Virology. 2001 Oct 10;289(1):150-63.

16.

Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.

Bolcic F, Laufer N, Torres C, Cassino L, Reynoso R, Quarleri J.

Antiviral Res. 2012 Aug;95(2):72-81. doi: 10.1016/j.antiviral.2012.05.015. Epub 2012 Jun 7.

PMID:
22683884
17.

Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy.

Chayama K, Suzuki F, Tsubota A, Kobayashi M, Arase Y, Saitoh S, Suzuki Y, Murashima N, Ikeda K, Takahashi N, Kinoshita M, Kumada H.

Hepatology. 2000 Nov;32(5):1138-44.

PMID:
11050067
18.

The amino acid sequence of the PKR-eIF2alpha phosphorylation homology domain of hepatitis C virus envelope 2 protein and response to interferon-alpha.

Cochrane A, Orr A, Shaw ML, Mills PR, McCruden EA.

J Infect Dis. 2000 Nov;182(5):1515-8. Epub 2000 Oct 9.

PMID:
11023475
19.

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayashi M, Arase Y, Ikeda K, Kumada H.

Intervirology. 2005;48(6):372-80.

PMID:
16024941
20.

Characterization of hepatitis C Virus genotype 3a hypervariable region 1 in patients achieved rapid virological response to alpha interferon and ribavirin combination therapy.

Akram M, Idrees M, Hussain A, Afzal S, Ilyas M, Zafar S, Aftab M, Badar S, Khubaib B.

Virol J. 2011 May 23;8:253. doi: 10.1186/1743-422X-8-253.

Supplemental Content

Support Center